PMC:7784786 / 11810-12054
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 412 | 6-14 | Species | denotes | patients | Tax:9606 |
| 414 | 153-163 | Chemical | denotes | itolizumab | MESH:C000597346 |
| 415 | 33-41 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 416 | 56-70 | Disease | denotes | critically ill | MESH:D016638 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T108 | 0-244 | Sentence | denotes | Three patients with diagnosis of COVID-19 classified as critically ill (two) and severely ill (one) were included in an expanded access trial to receive itolizumab in addition to standard treatment (http://rpcec.sld.cu/trials/RPCEC00000311-En). |